Aralez Pharmaceuticals Inc. announced that in connection with the company's winding down of its operations in connection with its bankruptcy proceedings, the employment by Company of the following individuals was or will be ceased, effective as of the dates noted below: Adrian Adams, Chief Executive Officer (January 31, 2019); Andrew Koven, President and Chief Business Officer (January 31, 2019); Jennifer Armstrong, Executive Vice President, Human Resources and Administration (January 31, 2019); Michael Kaseta, Chief Financial Officer (January 18, 2019). Mr. Adams will continue as a member of the Board of Directors of the Company. Effective as of January 18, 2019, Sanjay Subramanian, 43, the Company's current Treasurer, will assume the role of Chief Financial Officer.

Prior to joining the company, Mr. Subramanian was the Director of Treasury at Bausch Health Companies. Mr. Subramanian started his finance career at General Motors Co. where he held various positions before leaving as the Treasurer of GM Korea.

Effective as of January 31, 2019, Christopher Freeland, 40, the Company's current General Counsel, will also assume the role of Chief Operating Officer. Prior to being appointed as the Company's General Counsel, Mr. Freeland was the Company's Associate General Counsel. Prior to joining the Company, Mr. Freeland was an Associate General Counsel at American International Group.

Mr. Freeland started his legal career as a corporate associate at Willkie Farr & Gallagher LLP.